BACKGROUND: Current guidelines for managing Philadelphia-positive chronic myeloid leukemia include monitoring the expression of the BCR-ABL1 (breakpoint cluster region/c-abl oncogene 1, nonreceptor tyrosine kinase) fusion gene by quantitative reverse-transcription PCR (RT-qPCR). Our goal was to establish and validate reference panels to mitigate the interlaboratory imprecision of quantitative BCR-ABL1 measurements and to facilitate global standardization on the international scale (IS).
Residual disease in patients with chronic myeloid leukemia undergoing therapy with tyrosine kinase inhibitors is assessed by measuring the quantity of transcripts of the BCR-ABL1 (breakpoint cluster region/ c-abl oncogene 1, non-receptor tyrosine kinase) 17 fusion gene in peripheral white blood cells. This analysis is carried out with analytically sensitive molecular tests based on quantitative reverse-transcription PCR (RTqPCR) 18 technology (1-3 ) ; however, the wide array of preanalytical and analytical methods used worldwide and the lack of consensus guidelines have led to large variation in quantitative BCR-ABL1 measurements, which hinder interlaboratory comparative studies, patient portability, and harmonized definition of treatment response. In 2005, standardization of BCR-ABL1 reporting across tests and laboratories was established through a common international scale (IS) anchored to the baseline BCR-ABL1 expression levels of the IRIS study (International Randomized Study of Interferon vs STI571) (4, 5 ) . Achieving a 3-logarithm reduction from the standardized baseline level (defined as 100% IS) corresponds to the so-called major molecular response (MMR or 0.1% IS) and is associated in some studies with improvements in the long-term response to tyrosine kinase inhibitors and progression-free survival (6, 7 ) . In addition, the degree of molecular response at early time points has recently been shown to be predictive of overall survival (8, 9 ) .
Because of the prognostic value of MMR, a key goal of the IS standardization effort was to eliminate-or correct-the relative differences between MMR ascertainment and response rates across laboratories. The evaluation of representative sets of clinical specimens spanning at least 3 logarithms of detectable residual disease in both local and IS reference laboratories has provided an important proof of principle by significantly improving MMR concordance rates in about 50% of BCR-ABL1 testing laboratories (10, 11 ) . This approach also suffers from some obvious limitations, however. For example, both conversion factor (CF) establishment and validation require a set of 30 -40 clinical samples (10 ) , which can make the overall process lengthy and costly. Because there is no mechanism for continuous monitoring of performance, local and IS reference laboratories must either revalidate their CF each time a local method parameter is changed or risk drifting from the IS over time. Perhaps one of the most limiting features of the CF conversion process is that without sharing and testing of a common set of reference samples on a global scale, each sample exchange is an independent performance assessment relative to a single IS reference method.
It is likely that the comparability of BCR-ABL1 results would be improved by the availability of independent, broadly accessible external qualityassessment programs, such as the scheme recently launched by the United Kingdom National External Quality Assessment Service (12) (13) (14) . White blood cell lysates (11, 15 ) and leukemia cell lines (14, 16 ) have been successfully used in international comparative studies across BCR-ABL1 testing platforms and assay designs. In 2009, the Expert Committee on Biological Standardization of the WHO approved the first WHO International Genetic Reference Panel for quantification of BCR-ABL1 mRNA by RT-qPCR (17, 18 ) . This 4-level panel consists of freeze-dried e14a2-positive K562 cells diluted in a background of BCR-ABL1-negative HL-60 cells, with assigned reference values corresponding to the mean IS percent ratios obtained by repeat testing in multiple IS-standardized laboratories (18 ) . Unfortunately, the supply of WHO primary standards is limited, and their availability has been restricted to manufacturers of secondary reference standards (17, 18 ) . Armored RNA Quant (ARQ) (Asuragen) is a mature technology that may be well suited for the development of such secondary reference materials. These stable and commutable synthetic molecules have been extensively validated with multiple qualitative and quantitative tests for infectious diseases, and their performance has been fully evaluated against recognized biological international standards (19 -21 ) . More recently, their potential for use in oncology applications has also emerged (22, 23 ) . The aim of the broad collaborative study we describe was to develop robust synthetic ARQ reference panels calibrated to the mean IS percent ratios of the WHO primary standards in order to support the ongoing worldwide effort to standardize BCR-ABL1 quantitative measurements on the IS.
Materials and Methods

ARQ PREPARATIONS
Sequences of interest were cloned into pCR2.1 with the TA Cloning Kit (Life Technologies) and pairs of primers specific for each target (see the Report of Prototype Field Trial Evaluation and Fig. 1 in the online Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol59/ issue6). Inserts were subcloned in pT7T3-18-Kan (Asuragen) for RNA synthesis by in vitro transcription and subsequent packaging, as previously described (24 ) . The sequences of the 4 synthetic transcripts and an overview of the validated ARQ manufacturing and QC processes are shown in Figs. 1 and 2 in the online Data Supplement. The final concentrations of the packaged RNAs were measured by quantifying the phosphate groups within each transcript (see Supplemental Data Protocols in the online Data Supplement). Large-scale bulk ARQ preparations were formulated in buffer (10 mmol/L Tris, pH 7.0, 100 mmol/L NaCl, 1 mmol/L MgCl 2 ) and stored at 2°C-8°C. Panels formulated as described in the online Supplemental Data Protocols were stored below Ϫ15°C.
EXPERIMENTAL DESIGN AND DATA ANALYSES
Protocols and additional information on the experimental design for each Results section below are provided in the online Supplemental Data Protocols under their respective headings. All data analyses assumed a normal-like distribution of results after log 10 transformation of the percent ratios. Correction parameters (CPs) were calculated as described in the instructions for use of the ARQ IS calibrator panels. Correlation between results was assessed by least squares linear re-gression analyses and calculation of the corresponding slopes, standard errors of the slope, coefficients of determination (square of the Pearson product-moment correlation coefficient, or r 2 ), and standard errors of the residuals (root square of the sum of squared residual differences divided by the degrees of freedom). Differences between results were assessed by estimating the mean bias with the Bland-Altman method and calculating the 95% limits of agreement (LOA) (10, 25 ) . All P values were calculated at the 95% confidence level.
Results
ESTABLISHMENT OF COMMUTABLE SYNTHETIC MATERIALS
To generate a reproducible and lasting source of reference material, synthetic and nuclease-resistant ABL1, BCR, and BCR-ABL1 transcripts were prepared on a large scale with the validated ARQ manufacturing process (see Figs. 1 and 2 in the online Data Supplement). Transcripts were designed to contain the exonic sequences most commonly targeted by BCR-ABL1 RTqPCR assays ( Fig. 1A ; see Fig. 1 in the online Data Supplement). Four-level pilot panels containing a variable number of copies of e13a2 or e14a2 fusion transcripts in a constant background of control transcripts were evaluated in a large international field trial across 29 laboratories in 15 countries (see Report of Prototype Field Trial Evaluation in the online Data Supplement). This pilot study demonstrated the compatibility of the synthetic panels with independent RT-qPCR methods with 7 different RNA extraction protocols and 13 different platforms and highlighted their potential as commutable reference materials.
DEVELOPMENT OF PROTOTYPE CALIBRATOR PANELS
On the basis of the results of the pilot study and current recommendations for IS standardization (4, 5, 10, 11 ) , 4-level ARQ panels were formulated to cover a representative interval of percent ratios from Ͼ1% to Ͻ0.1% and were calibrated to the mean IS percent ratios of the WHO reference panel (Fig. 1B) . With this design, testing of the secondary ARQ IS calibrator panels in local laboratories would theoretically enable indirect comparison to the WHO primary standard, derivation of analytical CPs, and correction of local percent ratios to IS percent ratios if required (raw local percent ratio ϫ CP ϭ IS percent ratio; Fig. 1B ). Preliminary evaluation of the prototype panels showed that the ARQ calibrators could be processed with different RNA extraction methods optimized for the quantitative recovery of nucleic acids or be added directly to the reverse transcription reaction after a short heatdenaturation step (see Fig. 3 in the online Data Supplement). All subsequent experiments were therefore performed with the simple and rapid heat-lysis protocol to streamline the procedure and decrease the variability during the preanalytical steps. Repeat testing in 2 IS reference laboratories showed linear and reproducible detection of both e13a2 and e14a2 over 3 logarithms of IS percent ratios (Fig. 1C) . Accurate panel formulation and compatibility with the IS were confirmed for the ABL1 control transcript by the RT-qPCR method recommended by the Europe Against Cancer program (26, 27 ) (Fig. 1C , left panels) and for the BCR control transcript with the method used since 2001 to maintain the MMR reference value of the IRIS trial (2, 10, 28 ) (Fig. 1C , right panels). However, synthetic ARQ BCR-ABL1 cDNAs were inefficiently amplified with a third established qPCR primer/probe design (3, 11, 15 ) , producing a loss of calibrator 4 detection with or without RNA extraction and with different RT protocols (data not shown).
ANALYTICAL VALIDATION
To fully characterize the e13a2 and e14a2 ARQ IS calibrator panels, we conducted a series of analytical studies over a 2-year period. Duplicate analyses performed on 192 measures from 12 independent runs indicated that 95% of the paired percent ratios were within a 1.92-fold difference from each other with the expected increase in imprecision for lower percent ratios (Table  1 and Fig. 2A ). An interassay imprecision study of the mean of triplicate test results from 8 runs over 6 months showed the same pattern, with CVs of 14%, 23%, 28%, and 37% for calibrators 1-4 and a 95% LOA of 1.61-fold overall (Table 1 and Fig. 2B ). In both studies, the 4 calibrators covered 3 logarithms of percent ratios with a precisely linear fit and no significant difference between the ABL1 and BCR control transcripts (Table 1 ; see Fig. 4 in the online Data Supplement). Stability studies confirmed that each calibrator was reproducibly detected after 3, 6, 12, or 18 months of storage, with percent ratios all within the imprecision established for each calibrator level at time 0 (Fig. 2C) . Finally, the reproducibility of the overall process was validated with 3 independent consecutive lots of e13a2 and e14a2 calibrators manufactured over a 12-month period and with each lot being tested in 4 independent runs (Fig. 2D) . The same interval of percent ratios was observed with a precisely linear relationship between the 4 calibrator levels across 3 logarithms; similar levels of imprecision were observed for the 3 lots (18%-43% for the level-specific CV; Table 1 ). The evaluation of 2 independent lots in 2 IS-standardized laboratories 6 months apart also confirmed accurate and linear formulation across 3 logarithms of IS percent ratios (Fig.  1C and data not shown).
VALIDATION IN IS-STANDARDIZED LABORATORIES
To validate the accuracy of the ARQ IS calibrator panels, we conducted a second international field trial in 7 countries across 8 laboratories using either ABL1 (n ϭ 4) or BCR (n ϭ 4) control transcripts and various platforms and assay designs (2, 26 -29 ) . The e13a2 and e14a2 panels were tested in 3 independent runs at each site (192 measures overall), and the nominal IS percent ratios assigned to each calibrator level were compared directly with the IS percent ratios determined with in- dependent IS-standardized methods and laboratoryspecific CFs (raw local percent ratio ϫ CF ϭ IS percent ratio). The nominal and measured IS percent ratios were tightly correlated across the entire scale for both panels ( Table 2 ). The mean bias between the nominal and measured IS percent ratios for the 4 calibrator levels combined was Ͻ2.25-fold in all laboratories but one (e13a2 panel in laboratory 8) and 1.37-fold overall (Fig.  3A) . A comparison across laboratories showed no significant trend in the relative bias between ISstandardized methods (P Ͼ 0.05; Fig. 3B, left panel) . The level-specific interlaboratory CVs (18%-52%) were in the same range as previously reported for the 4-level WHO primary standards (14%-57%) (18 ) , with similar bias distributions and overall 95% LOA across 3 logarithms of IS percent ratios (Fig. 3B, right  panel) . Importantly, the calibrators were reproducibly detected at all levels, thereby enabling the derivation of analytical CPs and correction of the local raw percent ratios with laboratory-specific CPs (raw local percent ratio ϫ CP ϭ IS percent ratio). As expected, the resulting postcorrection bias was null [i.e., 1.00-fold, Fig. 3A (all data combined); see 
USAGE VALIDATION
To further validate the interlaboratory imprecision and the intended use of the ARQ IS calibrators, we evaluated the synthetic panels in 8 non-IS-standardized laboratories using the same commercial RT-qPCR assay that had previously been shown to be compatible with reporting on the IS (22 ) . Each laboratory followed the calibrators' instructions for use, which recommended 3 independent runs on different days for each panel (228 measures overall). The linear regression coefficients were similar (mean slope, 1.029; 95% CI, 0.994 -1.063), indicating strong correlation and absence of trend in the bias relative to the nominal IS percent ratios (Table 3) . Calculations of the mean bias for each laboratory produced CPs ranging from 0.369 to 0.648 with 95% LOA of 1.28-to 2.87-fold. The mean CP was 0.50 (95% CI, 0.43-0.57). After correction of the individual raw percent ratios with either the laboratoryspecific CP or the mean CP, the residual mean bias was null in both cases (postcorrection CP close to 1.00, Table 3). Establishment of a preliminary CF by sample exchange (n ϭ 61) in 2 different laboratories relative to 2 independent IS-standardized methods further showed an overall agreement in MMR classification of 91.8% between CP-corrected and CF-converted percent ratios, and 90.2% between CP-corrected and IS reference percent ratios (data not shown).
Discussion
Efficient monitoring of treatment response in chronic myeloid leukemia requires precise and accurate quantification of BCR-ABL1 expression across a wide linear dynamic interval of IS percent ratios (1, 4, 30 ) . For that reason, interlaboratory IS standardization cannot be achieved with a single reference sample. Both imprecision (intra-and interlaboratory reproducibility) and accuracy (mean bias relative to the IS) should be assessed across a clinically relevant interval of IS percent ratios (4, 8 -11 ) . We have demonstrated that 4-level synthetic calibrator panels reproducibly manufactured under controlled processes and directly anchored to the reference values of the WHO primary standards enable reproducible analytical calibration of local RTqPCR methods within the expected intra-and interlaboratory imprecision of IS-standardized methods.
Testing of the ARQ IS calibrator panels generates valuable information at multiple levels: (a) assessment of linearity, analytical sensitivity, and imprecision; (b) es- 
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timation of the mean bias and corresponding correction parameter, if required; and (c) estimation of the correlation between measures across the entire scale. We propose that the ARQ IS calibrator panels may be used as secondary IS reference materials to facilitate interlaboratory comparative studies or external quality-assessment programs.
To ensure the long-term adequacy and integrity of calibration measurements requires reference materials to be stable, homogeneous, traceable, and commutable. Synthetic transcripts have the advantage of being nuclease resistant, reproducible, well characterized, and linked to reference standards from the WHO and the NIST, but they are limited to specific sequence contents. Although all BCR-ABL1 assays must target the junction between BCR exon 13 or 14 and ABL1 exon 2, unfortunately no global consensus exists on the identity of the control gene. Therefore, the synthetic calibrator panels were designed to be compatible with a majority of laboratories using ABL1 or BCR control transcripts-about 80% of the assays used worldwide (4 ). To date, the calibrators have been evaluated in about 50 laboratories in 17 different countries on 5 continents, including 10 laboratories that use RTqPCR methods already standardized to the IS through sample-exchange programs. With the exception of 1 established assay design in which a single reverse primer targeting ABL1 exon 4 is used to generate long ABL1 and BCR-ABL1 e13a2 or e14a2 amplicons (3, 11, 15 ) , all evaluations were successful, with robust detection at all calibrator levels.
The synthetic calibrators are not process controls, and like white blood cell lysate or cell line reference samples, they cannot fully recapitulate the variety of clinicopathologic presentations, biological variation, and sample collection, storage, or shipping conditions encountered in the clinical setting. Direct processing with the heat-lysis protocol, however, decreases the likelihood of RNA loss or degradation during the preanalytical steps and also removes any variation potentially affecting the imprecision or analytical sensitivity of local RT-qPCR methods. It therefore preserves the stability and homogeneity of the calibrators, 2 important characteristics for an analytical reference material. In our study, the direct heat-lysis protocol was compatible with multiplex and singleplex methods, 1-and 2-step protocols, various real-time PCR instruments from multiple manufacturers, manual and automated setups, and commercial and laboratorydeveloped reagents (2, 22, 26 -29 ) , but it could not be evaluated with integrated closed assay systems such as the GenXpert instrument (31 ) .
Throughout the study, we observed remarkably stable 95% LOA Ͻ2.5-fold across multiple laboratories, assay designs, and platforms. The 95% LOA is a key performance metric because it is a global estimate of method imprecision across the entire interval of percent ratios assessed. Unlike other common metrics such as the CV, 95% LOA are appropriately calculated with normally distributed log-transformed values, provide quantitative information on the same unit as the measurement itself (-fold or logarithmic change), and allow easier interpretation of variation independently from the mean of the distribution (25 ) . In our study, all performance metrics were within the interval expected for the quantitative measurement of percent ratios from about 10% to Ͻ0.01%. For example, the interassay imprecision study produced CVs from 14% to 37% and 95% LOA from 1.21-to 2.09-fold for calibrators 1-4. Without adequate imprecision, a given RT-qPCR method cannot be accurately aligned to the IS, and its performance cannot be reproducibly monitored over time (5 ) . With a demonstrated variability of Ͻ2.5-fold over 3 logarithms of percent ratios, the synthetic calibrators enabled precise analytical assessments of distinct assay designs. Evaluations in 8 laboratories using the same reagents further highlighted the contribution of other parameters, such as operator, instrument, or raw data interpretation, to intralaboratory variability (95% LOA of 1.28-to 2.87-fold). Previous studies have shown that very large biases, sometimes Ͼ1 logarithm, can be efficiently corrected (10, 11 ) . Similarly, an analytical CP can be calculated to correct any amount of bias, provided the imprecision of the local RT-qPCR method is adequate (95% LOA of Ͻ2.5-fold) and there is no trend in the bias (slope of the least squares linear regression analysis). If the slope is between 0.90 and 1.10, the maximum potential error on the measurement of a change of 3 logarithms is 0.3 logarithms, or 2-fold. At MMR (a 3-logarithm change from IS baseline), that would be equivalent to measuring 0.1% on the IS between 0.05% and 0.2% at most, which is within the imprecision of current RT-qPCR methodologies (10 ) . For example, during the international field trial in 8 independent IS-standardized laboratories, the differences between measured IS percent ratios and nominal calibrator IS percent ratios were Ͻ2.25-fold for most laboratories, with an overall slope of 0.981. Because imprecision was low in all IS laboratories, 67.2% and 98.4% of the 192 individual measures were within 2-and 4-fold of the nominal IS percent ratios, respectively, well within the acceptance criteria defined for CF validity (10, 11 ) . (A), Relative difference between nominal and measured IS percent ratios for all calibrator levels combined. The relative differences (black diamond) for each laboratory and panel (e13a2 or e14a2) are sorted from the lowest to highest 95% LOA values (error bars). Overall results for all data combined (192 measures) using raw, CF-converted, or CP-corrected percent ratios are also shown on the right. (B), Bias analyses for the ARQ IS calibrator panels evaluated in the present study (left) and for the WHO primary standards (right) previously evaluated in 9 laboratories (18 ) . Each point represents the difference between laboratory-specific IS percent ratios and the reference IS percent ratios (mean IS percent ratios across all laboratories per fusion transcript and control transcript) plotted against the mean of both values. Black lines, mean bias. Dashed lines, 95% LOA. P, P value associated with the slope of the least squares linear regression.
The bias in 50% of the laboratories was Ͻ1.6-fold, corresponding to an agreement in MMR classification between CP-corrected and CF-converted IS percent ratios of at least 93% for a representative sample set covering 3 logarithms on the IS. Even with a maximum difference of 2.5-fold, only samples generating IS percent ratios between 0.04% and 0.25% would have the potential to be misclassified, within the imprecision of most RT-qPCR methods. The corresponding minimum MMR agreement would be 87% to 92% for samples covering 3 to 5 logarithms, which is within the interval previously reported for IS standardization via sample exchange (10, 11 ) . This expected performance was further confirmed by testing 61 representative clinical samples covering 3.36 logarithms of percent ratios with independent IS standardized methods and the commercial assay with a CP of 0.50 (agreement in MMR classification of 91.8%, with all discrepant IS percent ratios between 0.061% and 0.236%). In summary, our comprehensive study demonstrated that synthetic calibrators anchored to the WHO primary standards have the performance characteristics required to facilitate rapid and accurate calibration of BCR-ABL1 RT-qPCR methods to the IS. Ultimately, we expect the calibrators to reduce the need for BCR-ABL1 testing laboratories to complete the lengthy and costly process of CF establishment, validation, and periodic revalidation. In addition, the ARQ IS calibrator panels are reproducibly manufactured, broadly available, and commercially distributed worldwide, features that should enable dynamic monitoring of performance over time and further reduce the potential drift of methods already IS standardized. Finally, the rate of patients achieving an at least 4-logarithm decrease on the IS (MR 4.0 ) has increased substantially because of the advent of the second-generation tyrosine kinase inhibitors nilotinib and dasatinib (30, 32 ) . These extremely low to undetectable BCR-ABL1 concentrations must be carefully interpreted in the context of the exact number of ABL1 cDNA copies present in the qPCR; consequently, the absolute quantity of ABL1 transcripts should be comparable across testing laboratories (30 ) . Future studies will determine whether the synthetic calibrators whose copy numbers are precisely measured and traceable to a NIST Standard Reference Material can help further the standardization of these deep molecular responses below MMR. 
